{"id":239,"date":"2024-09-30T22:00:00","date_gmt":"2024-09-30T22:00:00","guid":{"rendered":"https:\/\/cninmed.com\/en\/?p=239"},"modified":"2025-09-07T13:45:35","modified_gmt":"2025-09-07T13:45:35","slug":"china-bd-2024-chimagen-and-gsk-enters-a-850-billion-usd-acquisition-on-cd19xcd20-targeted-tce-cmg1a46","status":"publish","type":"post","link":"https:\/\/cninmed.com\/en\/2024\/239.html","title":{"rendered":"[China BD 2024] Chimagen and GSK enters a 850 billion USD acquisition on CD19xCD20 targeted TCE CMG1A46"},"content":{"rendered":"\n<p>Announced Date: 2024-10-29 (October 29, 2024)<\/p>\n\n\n\n<p>Asset Name: CMG1A46<\/p>\n\n\n\n<p>Licensor: Chimagen Biosciences\u00a0 (China)<\/p>\n\n\n\n<p>Licensee (Buyer): GSK plc<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Asset Modality: T cell-engager (TCE)<\/p>\n\n\n\n<p>Asset Target: CD19 and CD20-targeted, CD3<\/p>\n\n\n\n<p>Potential Indication: B cell-driven autoimmune diseases, such as systemic lupus erythematosus (SLE) and lupus nephritis (LN), with potential to expand into related autoimmune diseases.<\/p>\n\n\n\n<p>Current Stage: Phase I clinical trials in leukaemia and lymphoma in both the US and China<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Scope of Authority:<\/p>\n\n\n\n<p>GSK will acquire full global rights of CMG1A46. <\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Payment Detail:<\/p>\n\n\n\n<p>Chimagen will be eligible to receive <\/p>\n\n\n\n<p>Upfront payment of\u00a0$300 million, <\/p>\n\n\n\n<p>Development and commercial milestone payments up to $550 million.<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Link:<\/p>\n\n\n\n<p><a href=\"https:\/\/www.gsk.com\/en-gb\/media\/press-releases\/gsk-enters-agreement-to-acquire-cmg1a46-from-chimagen-biosciences\/\">GSK enters agreement to acquire CMG1A46 from Chimagen Biosciences to expand immunology pipeline | GSK<\/a><\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Note:<\/p>\n\n\n\n<p>Chinese Name of \u201cChimagen Biosciences\u201c, &#8220;\u6069\u6c90\u751f\u7269&#8221;\u00a0<\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Announced Date: 2024-10-29 (October 29, 2024) Asset Name: CMG1A46 Licensor: Chimagen Biosciences\u00a0 (China) Licensee (Buyer): GSK &hellip; <a title=\"[China BD 2024] Chimagen and GSK enters a 850 billion USD acquisition on CD19xCD20 targeted TCE CMG1A46\" class=\"hm-read-more\" href=\"https:\/\/cninmed.com\/en\/2024\/239.html\"><span class=\"screen-reader-text\">[China BD 2024] Chimagen and GSK enters a 850 billion USD acquisition on CD19xCD20 targeted TCE CMG1A46<\/span>Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-239","post","type-post","status-publish","format-standard","hentry","category-china-license-out"],"_links":{"self":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/239","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/comments?post=239"}],"version-history":[{"count":2,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/239\/revisions"}],"predecessor-version":[{"id":242,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/239\/revisions\/242"}],"wp:attachment":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/media?parent=239"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/categories?post=239"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/tags?post=239"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}